Stock AnalizTeva Pharmaceutical Industries Ltd. TEVA
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Teva Pharmaceutical Industries Ltd. (TEVA) is a healthcare company listed in the US with a market value of about $51.9B. In the twelve months to September 30, 2026 it had revenue of $17.2B and net income of $506M, a net margin of 2.9%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a P/E of 103.5, a price to free cash flow of 42.0, 5-year revenue growth of 1% a year, a 5-year average ROIC of 1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 86% below the current price.
Score: 1.0 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- ROE above 15%
- Positive free cash flow
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.2B | $17.3B | $16.5B | $15.8B | $14.9B | $15.9B | $16.7B | $16.9B |
| Net income | $506M | $1.4B | -$1.6B | -$559M | -$2.4B | $417M | -$4.0B | -$999M |
| Free cash flow | $1.2B | $1.1B | $749M | $842M | $1.0B | $236M | $638M | $223M |
| EPS (diluted) | $0.43 | $1.21 | $-1.40 | $-0.48 | $-2.10 | $0.36 | $-3.42 | $-0.86 |
| Net margin | 2.9% | 8.2% | -9.9% | -3.5% | -16.4% | 2.6% | -23.9% | -5.9% |
| ROIC | — | 6.8% | -1.0% | 1.5% | -5.9% | 3.4% | -9.5% | -0.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $49.44, 11% above the current price; targets range from $42.12 to $57.00; the consensus rating is “Buy”; expected EPS is $2.06 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Teva Pharmaceutical Industries’s P/E ratio?
About 103.5, based on the last twelve months of diluted earnings per share (forward P/E about 15.7).
Is Teva Pharmaceutical Industries stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 86% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Teva Pharmaceutical Industries pay a dividend?
Not currently.
Is Teva Pharmaceutical Industries a good stock to buy?
We do not give buy or sell advice. Teva Pharmaceutical Industries scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.